Impact of l-citrulline on nitric oxide signaling and arginase activity in hypoxic human pulmonary artery endothelial cells.

Authors:
Douglass MS; Kaplowitz MR; Zhang Y; Fike CD.

Journal:
Pulm Circ

Publication Year: 2023

DOI:
10.1002/pul2.12221

PMCID:
PMC10091859

PMID:
37063746

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pulm Circ

Abbreviation: Pulm Circ

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Respiratory System

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Actigraphy methodology in the Kids Mod PAH trial: Physical activity as a functional endpoint in ped…
Avitabile CM; Krishnan US; Yung D and 16 more (2024) - Transparency Score: 3/6
Clinical evaluation of code-based algorithms to identify patients with pulmonary arterial hypertens…
Didden EM; Lu D; Hsi A and 3 more (2024) - Transparency Score: 3/6
CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonar…
Benza RL; Adamson PB; Bhatt DL and 4 more (2024) - Transparency Score: 3/6
Hemodynamic response to inhaled nitric oxide in patients with pulmonary hypertension and chronic ki…
Del Valle KT; Krowka MJ; Schinstock CA and 6 more (2024) - Transparency Score: 3/6
Patients with CTEPH and mild hemodynamic severity of disease improve to a similar level of exercise…
van Kan C; Tramper J; Bresser P and 8 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT Candice D. Fike is listed on a patent application for the use of lL‐citrulline‐citrulline as a therapeutic treatment for lung conditions."

Evidence found in paper:

"This work was supported in part by a K2R2 Award from the Primary Children's Hospital Foundation to C.D. Fike."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025